JP7837331B2 - Ｃｌｄｎ６及びｃｄ３に選択的に結合するポリペプチド構築物 - Google Patents

Ｃｌｄｎ６及びｃｄ３に選択的に結合するポリペプチド構築物

Info

Publication number
JP7837331B2
JP7837331B2 JP2023526547A JP2023526547A JP7837331B2 JP 7837331 B2 JP7837331 B2 JP 7837331B2 JP 2023526547 A JP2023526547 A JP 2023526547A JP 2023526547 A JP2023526547 A JP 2023526547A JP 7837331 B2 JP7837331 B2 JP 7837331B2
Authority
JP
Japan
Prior art keywords
seq
cdr
polypeptide
domain
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023526547A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023547662A5 (https=
JP2023547662A (ja
Inventor
ダールホフ，クリストフ
ラウム，トビアス
アンラーア，ヨーナス
ブルーメル，クラウディア
ガートケ，ラース
クヮッリャ，ジルケ
ホーナー，ヨーナス
ベイリス，ジュリー
ファム，エリザベス・ダン
ムロースキー，クリストファー・エム
アルバ，ベンジャミン・エム
Original Assignee
アムジェン リサーチ （ミュニック） ゲゼルシャフト ミット ベシュレンクテル ハフツング
アムジエン・インコーポレーテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アムジェン リサーチ （ミュニック） ゲゼルシャフト ミット ベシュレンクテル ハフツング, アムジエン・インコーポレーテツド filed Critical アムジェン リサーチ （ミュニック） ゲゼルシャフト ミット ベシュレンクテル ハフツング
Publication of JP2023547662A publication Critical patent/JP2023547662A/ja
Publication of JP2023547662A5 publication Critical patent/JP2023547662A5/ja
Application granted granted Critical
Publication of JP7837331B2 publication Critical patent/JP7837331B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2023526547A 2020-11-06 2021-11-08 Ｃｌｄｎ６及びｃｄ３に選択的に結合するポリペプチド構築物 Active JP7837331B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063110817P 2020-11-06 2020-11-06
US63/110,817 2020-11-06
US202163139419P 2021-01-20 2021-01-20
US63/139,419 2021-01-20
PCT/EP2021/080863 WO2022096700A1 (en) 2020-11-06 2021-11-08 Polypeptide constructs selectively binding to cldn6 and cd3

Publications (3)

Publication Number Publication Date
JP2023547662A JP2023547662A (ja) 2023-11-13
JP2023547662A5 JP2023547662A5 (https=) 2024-02-27
JP7837331B2 true JP7837331B2 (ja) 2026-03-30

Family

ID=78820148

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023526547A Active JP7837331B2 (ja) 2020-11-06 2021-11-08 Ｃｌｄｎ６及びｃｄ３に選択的に結合するポリペプチド構築物

Country Status (16)

Country Link
EP (1) EP4240770A1 (https=)
JP (1) JP7837331B2 (https=)
KR (1) KR20230098334A (https=)
AU (1) AU2021374036A1 (https=)
BR (1) BR112023008629A2 (https=)
CA (1) CA3199976A1 (https=)
CL (1) CL2023001310A1 (https=)
CO (1) CO2023006677A2 (https=)
CR (1) CR20230235A (https=)
IL (1) IL302586A (https=)
JO (1) JOP20230096A1 (https=)
MX (1) MX2023005343A (https=)
PE (1) PE20231516A1 (https=)
TW (1) TW202233679A (https=)
UY (1) UY39507A (https=)
WO (1) WO2022096700A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA54955A (fr) 2019-02-15 2021-12-22 Integral Molecular Inc Anticorps anti-claudine 6 et leurs utilisations
MX2022000111A (es) 2019-07-10 2022-02-10 Chugai Pharmaceutical Co Ltd Moleculas de union a claudina-6 y usos de las mismas.
TW202430574A (zh) 2022-11-30 2024-08-01 美商積分分子股份有限公司 針對密連蛋白６之抗體，包括其雙特異性格式

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016500059A (ja) 2012-11-13 2016-01-07 バイオエヌテック アーゲーＢｉｏＮＴｅｃｈ ＡＧ クローディンを発現するガン疾患を処置するための剤
WO2019135404A1 (en) 2018-01-05 2019-07-11 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing therapeutic agent
JP2019535234A (ja) 2016-09-23 2019-12-12 バイオンテック アーゲー クローディン発現がん疾患の処置のためのクローディン６又はクローディン１８．２とｃｄ３とに結合する二重特異的三価抗体
WO2020191344A1 (en) 2019-03-20 2020-09-24 The Regents Of The University Of California Claudin-6 bispecific antibodies

Family Cites Families (149)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3180193A (en) 1963-02-25 1965-04-27 Benedict David Machines for cutting lengths of strip material
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
WO1987005330A1 (en) 1986-03-07 1987-09-11 Michel Louis Eugene Bergh Method for enhancing glycoprotein stability
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
ATE243754T1 (de) 1987-05-21 2003-07-15 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
ATE108965T1 (de) 1987-12-09 1994-08-15 Omron Tateisi Electronics Co Induktives datenübertragungssystem.
US5476996A (en) 1988-06-14 1995-12-19 Lidak Pharmaceuticals Human immune system in non-human animal
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
US5683888A (en) 1989-07-22 1997-11-04 University Of Wales College Of Medicine Modified bioluminescent proteins and their use
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5292658A (en) 1989-12-29 1994-03-08 University Of Georgia Research Foundation, Inc. Boyd Graduate Studies Research Center Cloning and expressions of Renilla luciferase
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
DE69133557D1 (de) 1990-08-29 2007-03-15 Pharming Intellectual Pty Bv Homologe rekombination in säugetier-zellen
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2142801T3 (es) 1991-03-11 2000-05-01 Univ Georgia Res Found Clonacion y expresion de luciferasa de renilla.
WO1992022670A1 (en) 1991-06-12 1992-12-23 Genpharm International, Inc. Early detection of transgenic embryos
WO1992022645A1 (en) 1991-06-14 1992-12-23 Genpharm International, Inc. Transgenic immunodeficient non-human animals
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
GB9206422D0 (en) 1992-03-24 1992-05-06 Bolt Sarah L Antibody preparation
US7381803B1 (en) 1992-03-27 2008-06-03 Pdl Biopharma, Inc. Humanized antibodies against CD3
AU4541093A (en) 1992-06-18 1994-01-24 Genpharm International, Inc. Methods for producing transgenic non-human animals harboring a yeast artificial chromosome
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
PT672141E (pt) 1992-10-23 2003-09-30 Immunex Corp Metodos de preparacao de proteinas oligomericas soluveis
US5981175A (en) 1993-01-07 1999-11-09 Genpharm Internation, Inc. Methods for producing recombinant mammalian cells harboring a yeast artificial chromosome
JPH08509612A (ja) 1993-04-26 1996-10-15 ジェンファーム インターナショナル インコーポレイテッド 異種抗体を産生することができるトランスジェニック非ヒト動物
EP0759170B1 (en) 1993-09-10 2008-07-09 The Trustees Of Columbia University In The City Of New York Uses of green fluorescent protein
US5625825A (en) 1993-10-21 1997-04-29 Lsi Logic Corporation Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network
WO1995021191A1 (en) 1994-02-04 1995-08-10 William Ward Bioluminescent indicator based upon the expression of a gene for a modified green-fluorescent protein
US5643763A (en) 1994-11-04 1997-07-01 Genpharm International, Inc. Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating
US5777079A (en) 1994-11-10 1998-07-07 The Regents Of The University Of California Modified green fluorescent proteins
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5811524A (en) 1995-06-07 1998-09-22 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
ES2176484T3 (es) 1995-08-18 2002-12-01 Morphosys Ag Bancos de proteinas/(poli)peptidos.
KR100308764B1 (ko) 1995-08-29 2001-12-17 마나배게이사꾸 키메라동물및그의제작법
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
US5804387A (en) 1996-02-01 1998-09-08 The Board Of Trustees Of The Leland Stanford Junior University FACS-optimized mutants of the green fluorescent protein (GFP)
US5876995A (en) 1996-02-06 1999-03-02 Bryan; Bruce Bioluminescent novelty items
US5925558A (en) 1996-07-16 1999-07-20 The Regents Of The University Of California Assays for protein kinases using fluorescent protein substrates
US5976796A (en) 1996-10-04 1999-11-02 Loma Linda University Construction and expression of renilla luciferase and green fluorescent protein fusion genes
CA2722378C (en) 1996-12-03 2015-02-03 Amgen Fremont Inc. Human antibodies that bind tnf.alpha.
IL129767A0 (en) 1996-12-12 2000-02-29 Prolume Ltd Apparatus and method for detecting and identifying infectious agents
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
JP4327350B2 (ja) 1997-11-17 2009-09-09 マイクロメット アーゲー エピトープへの結合能力を保持する結合部位ドメインの同定のための新規方法
JP2002507410A (ja) 1998-03-27 2002-03-12 プロルーム・リミテッド ルシフェラーゼ、蛍光タンパク質、ルシフェラーゼおよび蛍光タンパク質をコードする核酸および、診断、高処理スクリーニングおよび新規アイテムにおけるその使用
US7112324B1 (en) 1998-04-21 2006-09-26 Micromet Ag CD 19×CD3 specific polypeptides and uses thereof
GB9815909D0 (en) 1998-07-21 1998-09-16 Btg Int Ltd Antibody preparation
AU5728999A (en) 1998-07-28 2000-02-21 Micromet Ag Heterominibodies
US7254167B2 (en) 1998-10-30 2007-08-07 Broadcom Corporation Constellation-multiplexed transmitter and receiver
AU776910B2 (en) 1998-12-08 2004-09-23 Merck Patent Gesellschaft Mit Beschrankter Haftung Modifying protein immunogenicity
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
US7230167B2 (en) 2001-08-31 2007-06-12 Syngenta Participations Ag Modified Cry3A toxins and nucleic acid sequences coding therefor
EP2319301B1 (en) 2001-11-30 2017-09-06 Amgen Fremont Inc. Transgenic animals bearing human Ig lambda light chain genes
US8486859B2 (en) 2002-05-15 2013-07-16 Bioenergy, Inc. Use of ribose to enhance plant growth
US7904068B2 (en) 2003-06-06 2011-03-08 At&T Intellectual Property I, L.P. System and method for providing integrated voice and data services utilizing wired cordless access with unlicensed spectrum and wired access with licensed spectrum
MXPA06004035A (es) 2003-10-16 2006-08-31 Micromet Ag Aglutinantes cd3 de-inmunizados multi-especificos.
CA2569509C (en) 2004-06-03 2014-08-12 Novimmune S.A. Anti-cd3 antibodies and methods of use thereof
EP2228698B1 (en) 2005-03-14 2012-06-27 Omron Corporation Programmable controller system
BRPI0611901A2 (pt) 2005-06-14 2012-08-28 Amgen, Inc composição, liofilizado, kit, e, processo para preparar uma composição
US8234145B2 (en) 2005-07-12 2012-07-31 International Business Machines Corporation Automatic computation of validation metrics for global logistics processes
BRPI0604215A (pt) 2005-08-17 2007-04-10 Biosigma Sa método para projetar oligonucleotìdeos para técnicas de biologia molecular
EP1940881B1 (en) 2005-10-11 2016-11-30 Amgen Research (Munich) GmbH Compositions comprising cross-species-specific antibodies and uses thereof
JP2007122396A (ja) 2005-10-27 2007-05-17 Hitachi Ltd ディスクアレイ装置及びその障害対応検証方法
TW200745163A (en) 2006-02-17 2007-12-16 Syntonix Pharmaceuticals Inc Peptides that block the binding of IgG to FcRn
US7919297B2 (en) 2006-02-21 2011-04-05 Cornell Research Foundation, Inc. Mutants of Aspergillus niger PhyA phytase and Aspergillus fumigatus phytase
US7574748B2 (en) 2006-03-07 2009-08-18 Nike, Inc. Glove with support system
US7990860B2 (en) 2006-06-16 2011-08-02 Harris Corporation Method and system for rule-based sequencing for QoS
US8430938B1 (en) 2006-07-13 2013-04-30 The United States Of America As Represented By The Secretary Of The Navy Control algorithm for autothermal reformer
KR101146588B1 (ko) 2006-08-11 2012-05-16 삼성전자주식회사 Ｆｉｎ 구조체 및 이를 이용한 핀 트랜지스터의 제조방법
CN100589507C (zh) 2006-10-30 2010-02-10 华为技术有限公司 一种拨号提示系统及方法
US7466008B2 (en) 2007-03-13 2008-12-16 Taiwan Semiconductor Manufacturing Company, Ltd. BiCMOS performance enhancement by mechanical uniaxial strain and methods of manufacture
RS53008B2 (sr) 2007-04-03 2022-12-30 Amgen Res Munich Gmbh Interspecijski specifičan cd3-epsilon vezujući domen
US8209741B2 (en) 2007-09-17 2012-06-26 Microsoft Corporation Human performance in human interactive proofs using partial credit
US8464584B2 (en) 2007-10-19 2013-06-18 Food Equipment Technologies Company, Inc. Beverage dispenser with level measuring apparatus and display
DE112008003168B4 (de) 2007-11-29 2022-01-05 Schaeffler Technologies AG & Co. KG Kraftübertragungsvorrichtung, insbesondere zur Leistungsübertragung zwischen einer Antriebsmaschine und einem Abtrieb
EP2241578B1 (en) * 2008-01-11 2016-04-20 The University of Tokyo Anti-cldn6 antibody
US8376279B2 (en) 2008-01-23 2013-02-19 Aurora Flight Sciences Corporation Inflatable folding wings for a very high altitude aircraft
WO2009127691A1 (en) 2008-04-17 2009-10-22 Ablynx N.V. Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same
US20110293619A1 (en) * 2008-10-01 2011-12-01 Micromet Ag CROSS-SPECIES-SPECIFIC PSMAxCD3 BISPECIFIC SINGLE CHAIN ANTIBODY
EP2352765B1 (en) 2008-10-01 2018-01-03 Amgen Research (Munich) GmbH Cross-species-specific single domain bispecific single chain antibody
CN102341172A (zh) 2009-03-04 2012-02-01 日产自动车株式会社 废气净化催化剂及其制造方法
US8463191B2 (en) 2009-04-02 2013-06-11 Qualcomm Incorporated Beamforming options with partial channel knowledge
EP2493921B1 (en) 2009-10-30 2018-09-26 Albumedix Ltd Albumin variants
US20130225496A1 (en) 2010-11-01 2013-08-29 Novozymes Biopharma Dk A/S Albumin Variants
EP2658739B1 (de) 2010-12-30 2017-02-22 Johnson Controls Metals and Mechanisms GmbH & Co. KG Längsverstellvorrichtung eines kraftfahrzeugsitzes mit zwei schienenpaaren
CA2830660A1 (en) 2011-05-05 2012-11-08 Novozymes Biopharma Dk A/S Albumin variants
ES2989943T3 (es) * 2011-05-13 2024-11-28 Astellas Pharma Inc Anticuerpos para el tratamiento de un cáncer que expresa la Claudina 6
WO2013026837A1 (en) 2011-08-23 2013-02-28 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
NO2748201T3 (https=) 2011-08-23 2018-05-12
EP2780364A2 (en) 2011-11-18 2014-09-24 Eleven Biotherapeutics, Inc. Proteins with improved half-life and other properties
DK2825556T3 (en) 2012-03-16 2018-04-16 Albumedix As albumin Variants
MX2015005363A (es) 2012-11-08 2015-11-06 Novozymes Biopharma Dk As Variantes de albumina.
WO2014075697A1 (en) * 2012-11-13 2014-05-22 Biontech Ag Agents for treatment of claudin expressing cancer diseases
US20140302037A1 (en) 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
US20140308285A1 (en) 2013-03-15 2014-10-16 Amgen Inc. Heterodimeric bispecific antibodies
US11634502B2 (en) 2013-03-15 2023-04-25 Amgen Inc. Heterodimeric bispecific antibodies
CA2919076C (en) 2013-07-31 2024-01-30 Amgen Inc. Stabilization of fc-containing polypeptides
US20160257748A1 (en) 2013-09-25 2016-09-08 Amgen Inc. V-c-fc-v-c antibody
US10105142B2 (en) 2014-09-18 2018-10-23 Ethicon Llc Surgical stapler with plurality of cutting elements

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016500059A (ja) 2012-11-13 2016-01-07 バイオエヌテック アーゲーＢｉｏＮＴｅｃｈ ＡＧ クローディンを発現するガン疾患を処置するための剤
JP2019535234A (ja) 2016-09-23 2019-12-12 バイオンテック アーゲー クローディン発現がん疾患の処置のためのクローディン６又はクローディン１８．２とｃｄ３とに結合する二重特異的三価抗体
WO2019135404A1 (en) 2018-01-05 2019-07-11 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing therapeutic agent
WO2020191344A1 (en) 2019-03-20 2020-09-24 The Regents Of The University Of California Claudin-6 bispecific antibodies

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Yolanda S. KAP et al.，"A Monoclonal Antibody Selection for Immunohistochemical Examination of Lymphoid Tissues From Non-human Primates"，Journal of Histochemistry & Cytochemistry，2009年09月03日，Vol. 57, No. 12，p.1159-1167，DOI: 10.1369/jhc.2009.954123

Also Published As

Publication number Publication date
IL302586A (en) 2023-07-01
UY39507A (es) 2022-03-31
CR20230235A (es) 2023-10-05
WO2022096700A1 (en) 2022-05-12
AU2021374036A1 (en) 2023-06-08
CA3199976A1 (en) 2022-05-12
BR112023008629A2 (pt) 2023-10-03
KR20230098334A (ko) 2023-07-03
JOP20230096A1 (ar) 2023-05-04
EP4240770A1 (en) 2023-09-13
TW202233679A (zh) 2022-09-01
CO2023006677A2 (es) 2023-06-09
PE20231516A1 (es) 2023-09-28
JP2023547662A (ja) 2023-11-13
CL2023001310A1 (es) 2023-12-01
MX2023005343A (es) 2023-05-22

Similar Documents

Publication Publication Date Title
US20240174745A1 (en) Antibody Constructs for CLDN18.2 and CD3
KR20180033501A (ko) Dll3 및 cd3에 결합하는 이중특이적인 항체 작제물
KR20180037950A (ko) 메소텔린 및 cd3에 결합하는 이중특이적 항체 작제물
JP7837331B2 (ja) Ｃｌｄｎ６及びｃｄ３に選択的に結合するポリペプチド構築物
JP7805362B2 (ja) Ｃｄ３に結合するポリペプチド構築物
US20230406887A1 (en) Antigen binding domain with reduced clipping rate
CA3107192C (en) Antibody constructs for cldn18.2 and cd3
EA051514B1 (ru) Полипептидные конструкции, селективно связывающиеся с cldn6 и cd3
CN116685606A (zh) 选择性地与cldn6和cd3结合的多肽构建体
EA050517B1 (ru) Антигенсвязывающий домен с пониженной скоростью расщепления
EA048433B1 (ru) Конструкции на основе антител для связывания cldn18.2 и cd3
EA043696B1 (ru) Биспецифические конструкции антител к psma и cd3, вовлекающие т-клетки

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240215

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240215

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250425

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250520

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250812

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251021

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251216

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260303

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260317

R150 Certificate of patent or registration of utility model

Ref document number: 7837331

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150